Document 2436
 DOCN  M94A2436
 TI    Discordant evolution of HIV and HCV serologies in IVDUs: a four years
       retrospective study.
 DT    9412
 AU    Mansuy JM; Lheritier D; Puchot P; Puppo P; Gayet C; Izopet J; Puel J;
       Laboratoire de Virologie, CHU Purpan, Toulouse, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):304 (abstract no. PC0147). Unique
       Identifier : AIDSLINE ICA10/94370139
 AB    OBJECTIVES: To evaluate the course of HIV and HCV serological markers in
       a IVDU population since 1990. METHODS: All patients were IVDUs before
       the serological tests and were followed in a drug-weaning institution
       (Centre L. Engelmejer/IDRET). HIV and HCV serologies were performed in
       1417 subjects (1110 males, 307 females) by EIA methods. Positives
       results were confirmed by an immunoblot (LAV Blot 1 Diagnostics Pasteur,
       RIBA II, III Ortho Diagnostic System). Khi2 test was used for
       statistical analysis. RESULTS: TABULAR DATA, SEE ABSTRACT SEE VOLUME.
       Frequency of HIV positive serologies decreased (from 69.8% to 34.2%)
       during follow up (p < 0.0001). In contrast, we observed a significant (p
       = 0.009) increased of HCV positive serologies from 1990 to 1992.
       Serologies performed in 1993 showed decrease (p = 0.002) of HCV
       seroprevalence among the IVDUs studies. CONCLUSION: The decrease of HIV
       seroprevalence among the population studied is an important fact. Such a
       decrease may be correlated to a sudden awareness of the epidemiologic
       risk by the IVDUs and to the recent measure of the French Department of
       the Health (uncontrolled syringes released). The increase of the HCV+
       population among IVDUs between 1990 and 1992 is dramatic. However, we
       cannot exclude that this result could reflect higher sensibility of the
       third generation diagnostic kits (since middle of the 92th). The HCV
       seroprevalence increase was not confirmed in 1993, thus we suggest that
       this evolution should be confirmed in the next years.
 DE    Female  France/EPIDEMIOLOGY  Hepatitis Antibodies/*ANALYSIS  Hepatitis
       C/EPIDEMIOLOGY/TRANSMISSION  Hepatitis C Viruses/IMMUNOLOGY  Human  *HIV
       Seropositivity  HIV Seroprevalence  Male  Retrospective Studies
       Substance Abuse, Intravenous/*COMPLICATIONS/IMMUNOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).